Nutritional considerations in pediatric inflammatory bowel disease

Expert Review of Gastroenterology and Hepatology

Volumn 4, Issue 3, 2010, Pages 305-317

  Conklin, Laurie S ^a   Oliva Hemker, Maria ^b  

^a CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Children; Crohn's disease; Enteral; Growth; Inflammatory bowel disease; Micronutrient deficiency; Nutrition; Pediatric; Ulcerative colitis

Indexed keywords

5 ACETAMIDOSALICYLIC ACID; BUDESONIDE; CALCIUM; CORTICOSTEROID; CURCUMIN; CYANOCOBALAMIN; FERRIC CARBOXYMALTOSE; FERRIC HYDROXIDE SUCROSE; FERROUS FUMARATE; FERROUS SULFATE; FISH OIL; FLUORIDE; FOLIC ACID; FOLINIC ACID; GREEN TEA EXTRACT; HEPCIDIN; INTERLEUKIN 6; IRON; MESALAZINE; METHOTREXATE; OMEGA 3 FATTY ACID; PAMIDRONIC ACID; PLACEBO; PREDNISOLONE; PREDNISONE; SALAZOSULFAPYRIDINE; STAT3 PROTEIN; VITAMIN D; VITAMIN K GROUP;

ABDOMINAL PAIN; ANEMIA; BONE DENSITY; BONE TURNOVER; CHILD NUTRITION; CHRONIC INFLAMMATION; COLITIS; CROHN DISEASE; CYANOCOBALAMIN DEFICIENCY; DIARRHEA; DIET SUPPLEMENTATION; DRUG DOSE INCREASE; DRUG WITHDRAWAL; ENTERIC FEEDING; ENTERITIS; FACE RASH; FOLIC ACID DEFICIENCY; FRACTURE; GASTROINTESTINAL SYMPTOM; GROWTH DISORDER; HUMAN; HYPOGONADISM; IRON DEFICIENCY; MALNUTRITION; NAUSEA; NONHUMAN; NUTRITIONAL ASSESSMENT; OSTEOPENIA; PERIPHERAL EDEMA; RECOMMENDED DRUG DOSE; REVIEW; RHEUMATOID ARTHRITIS; SCREENING; SIDE EFFECT; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT; VITAMIN D DEFICIENCY; VITAMIN K DEFICIENCY; ZINC DEFICIENCY; ADULT; ANEMIA, IRON-DEFICIENCY; BONE; CHILD; DIET THERAPY; FEMALE; INFLAMMATORY BOWEL DISEASES; MALE; MIDDLE AGED; NUTRITIONAL STATUS; PATHOLOGY; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ADRENAL CORTEX HORMONES; ADULT; ANEMIA, IRON-DEFICIENCY; BONE AND BONES; BONE DENSITY; CHILD; ENTERAL NUTRITION; FEMALE; GUIDELINES AS TOPIC; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; MALNUTRITION; MIDDLE AGED; NUTRITIONAL STATUS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 77953273592     PISSN: 17474124     EISSN: None     Source Type: Journal    
DOI: 10.1586/egh.10.23     Document Type: Review

References (135)

1. Loftus CG, Loftus EV Jr, Harmsen WS et al. Update on the incidence and prevalence of Crohn's disease and ulcerative colitis in Olmstead County, Minnesota 1940-2000. Inflamm. Bowel Dis. 13(3), 254-261 (2007).
2. Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology 126(6), 1504-1517 (2004).
3. Kelsen J, Baldassano R. Inflammatory bowel disease: the difference between children and adults. Inflamm. Bowel Dis. 14(Suppl. 2), S9-S11 (2008).
4. Heuschkel R, Salvestrini C, Beattie RM et al. Guidelines for the management of growth failure in childhood inflammatory bowel disease. Inflamm. Bowel Dis. 14(6), 839-849 (2008).
5. Motil KJ, Grand RJ, Davis-Kraft L, Ferlic LL, Smith EO. Growth failure in children with inflammatory bowel disease: a prospective study. Gastroenterology 105(3), 681-691 (1993).
6. Markowitz J, Grancher K, Rosa J, Aiges H, Daum F. Growth failure in pediatric inflammatory bowel disease. J. Pediatr. Gastroenterol. Nutr. 16(4), 373-380 (1993).
7. Markowitz J, Daum F. Growth impairment in pediatric inflammatory bowel disease. Am. J. Gastroenterol. 89(3), 319-326 (1994).
8. Kanof ME, Lake AM, Bayless TM. Decreased height velocity in children and adolescents before the diagnosis of Crohn's disease. Gastroenterology 95(6), 1523-1527 (1988).
9. Griffiths AM, Nguyen P, Smith C, MacMillan JH, Sherman PM. Growth and clinical course of children with Crohn's disease. Gut 34(7), 939-943 (1983).
10. Sawczenko A, Ballinger AB, Savage MO, Sanderson IR. Clinical features affecting final adult height in patients with pediatric-onset Crohn's disease. Pediatrics 118(1), 124-129 (2006).
11. Sylvester FA, Leopold S, Lincoln M, Hyams JS, Griffiths AM, Lerer T. A two-year longitudinal study of persistent lean tissue deficits in children with Crohn's disease. Clin. Gastroenterol. Hepatol. 7(4), 452-455 (2009).
12. Mudter J, Weigmann B, Bartsch B et al. Activation pattern of signal transducers and activators of transcription (STAT) factors in inflammatory bowel diseases. Am. J. Gastroenterol. 100(1), 64-72 (2005).
13. Brown KA, Back SJ, Ruchelli ED et al. Lamina propria and circulating IL-6 in newly diagnosed pediatric inflammatory bowel disease patients. Am. J. Gastroenterol. 97(10), 2603-2608 (2002).
14. Carey R, Jurickova I, Ballard E et al. Activation of an IL-6: STAT3-dependent transcriptome in pediatric-onset inflammatory bowel disease. Inflamm. Bowel Dis. 14(4), 446-457 (2008).
15. Sawczenko A, Azooz O, Paraszczuk J et al. Intestinal inflammation-induced growth retardation acts through IL-6 in rats and depends on the e-174 IL-6 G/C polymorphism in children. Proc. Natl Acad. Sci. USA 102(37), 13260-13265 (2005).
16. Ballinger AB, Azooz O, El-Haj T et al. Growth failure occurs through a decrease in insulin-like growth factor 1 which is independent of undernutrition in a rat model of colitis. Gut 46(5), 694-700 (2000).
17. Pereira RC, Delany AM, Canalis E. Effects of cortisol and bone morphogenetic protein-2 on stromal cell differentiation: correlation with CCAAT-enhancer binding protein expression. Bone 30(5), 685-691 (2002).
18. Hyams JS, Carey DE. Corticosteroids and growth. J. Pediatr. 113(2), 249-254 (1988).
19. Ballinger AB, Savage MO, Sanderson IR. Delayed puberty associated with inflammatory bowel disease. Pediatr. Res. 53(2), 205-210 (2003).
20. Allen DB. Influence of inhaled corticosteroids on growth: a pediatric endocrinologist's perspective. Acta Paediatr. 87(2), 123-129 (1998).
21. Schoon EJ, Bollani S, Mills PR et al. Bone mineral density in relation to efficacy and side effects of budesonide and prednisolone in Crohn's disease. Clin. Gastroenterol. Hepatol. 3(2), 113-121 (2005).
22. Markowitz J, Grancher K, Kohn N, Lesser M, Daum F. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology 119(4), 895-902 (2000).
23. Punati J, Markowitz J, Lerer T et al. Effect of early immunomodulator use in moderate to severe pediatric Crohn disease. Inflamm. Bowel Dis. 14(7), 949-953 (2008).
24. Walters TD, Gilman AR, Griffiths AM. Linear growth improves during infliximab therapy in children with chronically active severe Crohn's disease. Inflamm. Bowel Dis. 13(4), 424-430 (2007).
25. Markowitz J, Hyams J, Mack D et al. Corticosteroid therapy in the age of infliximab: acute and 1-year outcomes in newly diagnosed children with Crohn's disease. Clin. Gastroenterol. Hepatol. 4(9), 1124-1129 (2006).
26. Pfefferkorn M, Burke G, Griffiths A et al. Growth abnormalities persist in newly diagnosed children with Crohn disease despite current treatment paradigms. J. Pediatr. Gastroenterol. Nutr. 48(2), 168-174 (2009).
27. Bernstein CN, Leslie WD, Leboff MS et al. AGA technical review on osteoporosis in gastrointestinal diseases. Gastroenterology 124(3), 795-841 (2003).
28. Leonard MB. Glucocorticoid-induced osteoporosis in children: impact of the underlying disease. Pediatrics 119(Suppl. 2), S166-S174 (2007).
29. Bourges O, Dorgeret S, Alberti C et al. Low bone mineral density in children with Crohn's disease. Arch. Pediatr. 11(7), 800-806 (2004).
30. Gupta A, Paski S, Issenman R, Webber C. Lumbar spine bone mineral density at diagnosis and during follow-up in children with IBD. J. Clin. Densitom. 7(3), 290-295 (2004).
31. Schmidt S, Mellström D, Norjavaara E, Sundh SV, Saalman R. Low bone mineral density in children and adolescents with inflammatory bowel disease: a population based study from western Sweden. Inflamm. Bowel Dis. 15(2), 1844-1850 (2009).
32. Sylvester FA, Wyzga N, Hyams JS et al. Natural history of bone metabolism and bone mineral density in children with inflammatory bowel disease. Inflamm. Bowel Dis. 13(1), 42-50 (2007).
33. Paganelli M, Albanese C, Borrelli O et al. Inflammation is the main determinant of low bone mineral density in pediatric inflammatory bowel disease. Inflamm. Bowel Dis. 13(4), 416-423 (2007).
34. Dubner SE, Shults J, Baldassano RN et al. Longitudinal assessment of bone density and structure in an incident cohort of children with Crohn's disease. Gastroenterology 136, 123-130 (2009).
35. Johnell O, Kanis JA, Oden A et al. Predictive value of BMD for hip and other fractures. J. Bone Miner. Res. 20(7), 1185-1194 (2005).
36. Persad R, Jaffer I, Issenman RM. The prevalence of long bone fractures in pediatric inflammatory bowel disease. J. Pediatr. Gastroenterol. Nutr. 43(5), 597-602 (2006).
37. Loftus EV Jr, Crowson CS, Sandborn WJ, Tremaine WJ, O'Fallon WB, Melton LJ 3rd. Long-term fracture risk in patients with Crohn's disease: a population-based study in Olmstead Minnesota. Gastroenterology 123(2), 468-475 (2002).
38. Card T, West J, Hubbard R, Logan RF. Hip fractures in patients with inflammatory bowel disease and their relationship to corticosteroid use. Gut 53(2), 251-255 (2004).
39. Klaus J, Armbrecht G, Steinkamp M et al. High prevalence of osteoporotic vertebral fractures in patients with Crohn's disease. Gut 51(5), 654-658 (2002).
40. American Gastroenterological Assocation medical position statement: guidelines on osteoporosis in gastrointestinal disease. Gastroenterology 124(3), 791-794 (2003).
41. Lewiecki EM, Gordon CM, Baim S et al. International society for clinical densitometry 2007 adult and pediatric official positions. Bone 43, 1115-1121 (2008).
42. Filippi J, Al-Jaouni R, Wiroth JB, Hebuterne X, Schneider SM. Nutritional deficiencies in patients with Crohn's disease in remission. Inflamm. Bowel Dis. 12(3), 185-191 (2006).
43. Gasche C, Dejaco C, Waldhoer T et al. Intravenous iron and erythropoietin for anemia associated with Crohn disease. Ann. Intern. Med. 126(10), 782-787 (1997).
44. Beeken W. Absorptive defects in young people with regional enteritis. Pediatrics 52(1), 69-74 (1973).
45. Kugathasan S, Judd RH, Hoffman RG et al. Epidemiologic characteristics of children with newly diagnosed inflammatory bowel disease in Wisconsin: a statewide population-based study. J. Pediatr. 143(4), 525-531 (2003).
46. Gasche C, Berstad A, Befrits R et al. Guidelines on the diagnosis and management of iron deficiency and anemia in inflammatory bowel diseases. Inflamm. Bowel Dis. 13(12), 1545-1553 (2007).
47. Semrin G, Fishman DS, Bousvaros A et al. Impaired intestinal iron absorption in Crohn's disease correlates with disease activity and markers of inflammation. Inflamm. Bowel Dis. 12 (12), 1101-1106 (2006).
48. Thayu M, Mamula P. Treatment of iron deficiency anemia in pediatric inflammatory bowel disease. Curr. Treat. Options Gastroenterol. 8(5), 411-417 (2005).
49. de Silva AD, Mylonaki M, Rampton DS. Oral iron therapy in inflammatory bowel disease: usage, tolerance, and efficacy. Inflamm. Bowel Dis. 9(5), 316-320 (2003).
50. Gisbert JP, Bermejo F, Pajares R et al. Oral and intravenous iron treatment in inflammatory bowel disease: hematological response and quality of life improvement. Inflamm. Bowel Dis. 15(10), 1485-1491 (2009).
51. Erichsen K, Hausken T, Ulvik RJ et al. Ferrous fumarate deteriorated plasma antioxidant status in patients with Crohn disease. Scand. J. Gastroenterol. 38(5), 543-548 (2003).
52. Oldenburg B, van Berge Henegouwen GP, Rennick D, Van Asbeck BS, Koningsberger JC. Iron supplementation affects the production of pro-inflammatory cytokines in IL-10 deficient mice. Eur. J. Clin. Invest. 30(6), 505-510 (2000).
53. Uritski R, Barshack I, Bilkis I, Ghebremeskel K, Reifen R. Dietary iron affects inflammatory status in a rat model of colitis. J. Nutr. 134(9), 2251-2255 (2004).
54. Seril DN, Liao J, Ho KL, Warsi A, Yang CS, Yang GY. Dietary iron supplementation enhances DSS-induced colitis and associated colorectal carcinoma development in mice. Dig. Dis. Sci. 47(6), 1266-1278 (2002).
55. Schröder O, Mickisch O, Seidler U et al. Intravenous iron sucrose versus oral iron supplementation for the treatment of iron deficiency anemia in patients with inflammatory bowel disease - a randomized, controlled, open-label, multicenter study. Am. J. Gastroenterol. 100(11), 2503-2509 (2005).
56. Kulnigg S, Teischinger L, Dejaco C, Waldhör T, Gasche C. Rapid recurrence of IBD-associated anemia and iron deficiency after intravenous iron sucrose and erythropoietin treatment. Am. J. Gastroentererol. 104(6), 1460-1467 (2009).
57. Kulnigg S, Stoinov S, Simanenkov V et al. A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric caroxymaltose (FERINJECT® ) randomized controlled trial. Am. J. Gastroenterol. 103(5), 1182-1192 (2008).
58. Ooi BC, Barnes GL, Tauro GP. Normalization of vitamin B12 absorption after ileal resection in children. J. Paediatr. Child Health 28(2), 168-171 (1992).
59. Headstrom PD, Rulyak SJ, Lee SD. Prevalence of and risk factors for vitamin B12 deficiency in patients with Crohn's disease. Inflamm. Bowel Dis. 14(2), 217-223 (2008).
60. Duerksen DR, Fallows G, Bernstein CN. Vitamin B12 malabsorption in patients with limited ileal resection. Nutrition 22(11-12), 1210-1213 (2006).
61. Coull DB, Tait RC, Anderson JH, McKee RF, Finlay IG. Vitamin B12 deficiency following restorative proctolcolectomy. Colorectal Dis. 9(6), 562-566 (2007).
62. Vidal-Alaball J, Butler CC, Cannings-John R et al. Oral vitamin B12 versus intramuscular vitamin B12 for vitamin B12 deficiency. Cochrane Database Syst. Rev. 3, CD004655 (2005).
63. Kim YI. Role of folate in colon cancer development and progression. J. Nutr. 133(11 Suppl. 1), 373S-379S (2003).
64. Phelip JM, Ducros V, Faucheron JL, Flourie B, Roblin X. Association of hyperhomocysteinemia and folate deficiency with colon tumors in patients with inflammatory bowel disease. Inflamm. Bowel Dis. 14(2), 242-248 (2008).
65. Lashner BA, Heidenreich PA, Su GL, Kane SV, Hanauer SB. Effect of folate supplementation on the incidence of dysplasia and cancer in chronic ulcerative colitis. A case-control study. Gastroenterology 97(2), 255-259 (1989).
66. Ebbing M, Bønaa KH, Nygård O et al. Cancer incidence and mortality after treatment with folic acid and vitamin B12. JAMA 302(19), 2119-2126 (2009).
67. Fife J, Raniga S, Hider PN, Frizelle FA. Folic acid supplementation and colorectal cancer risk: a meta-analysis. Colorectal Dis. DOI: 10.1111/j.1463-1318.2009.02089.x (2009) (Epub ahead of print).
68. Chowers Y, Sela BA, Holland R, Fidder H, Simoni FB, Bar-Meir S. Increased levels of homocysteine in patients with Crohn's disease are related to folate levels. Am. J. Gastroenterol. 95(12), 3498-3502 (2000).
69. Vagianos K, Bector S, McConnell J, Bernstein CN. Nutrition assessment of patients with inflammatory bowel disease. JPEN J. Parenter. Enteral Nutr. 31(4), 311-319 (2007).
70. Heymann MB, Garnett EA, Shaikh N et al. Folate concentrations in pediatric patients with newly diagnosed inflammatory bowel disease. Am. J. Clin. Nutr. 89(2), 545-550 (2009).
71. Ortiz Z, Shea B, Suarez Almazor M, Moher D, Wells G, Tugwell P. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. Cochrane Database Syst. Rev. 2, CD000951 (2000).
72. Griffith SM, Fisher J, Clarke S et al. Do patients with rheumatoid arthritis established on methotrexate and folic acid 5 mg daily need to continue folic acid supplements long term? Rheumatology 39(10), 1102-1109 (2000).
73. van Ede AE, Laan RF, Rood MJ et al. Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum. 44(7), 1515-1524 (2001).
74. Krogh Jensen M, Ekelund S, Svendsen L. Folate and homocysteine status and haemolysis in patients treaded with sulphasalazine for arthritis. Scand. J. Clin. Lab. Invest. 56(5), 421-429 (1996).
75. Jansen G, van der Heijden J, Oerlemans R et al. Sulfasalazine is a potent inhibitor of the reduced folate carrier: implications for combination therapies with methotrexate in rheumatoid arthritis. Arthritis Rheum. 50(7), 2130-2139 (2004).
76. Norman AW, Bouillon R, Whiting SJ et al. 13th workshop consensus for vitamin D nutritional guidelines. J. Steroid Biochem. Mol. Biol. 103(3-5), 204-205 (2007).
77. Heaney RP, Dowell MS, Hale CA, Bendich A. Calcium absorption varies within the reference range for serum 25-hydroxyvitamin D. J. Am. Coll. Nutr. 22(2), 142-146 (2003).
78. Misra M, Pacaud D, Petryk A, Collett-Solberg PF, Kappy M. Vitamin D deficiency in children and its management: review of current knowledge and recommendations. Pediatrics 122(2), 398-417 (2008).
79. Saintonge S, Bang H, Gerber LM. Implications of a new definition of vitamin D deficiency in a multiracial US adolescent population, the National Health and Nutrition Examination Survey III. Pediatrics 123(3), 797-803 (2009).
80. Siffledeen JS, Siminoski K, Steinhart H, Greenberg G, Fedorak RN. The frequency of vitamin D deficiency in adults with Crohn's disease. Can. J. Gastroenterol 17(8), 473-478 (2003).
81. McCarthy D, Duggan P, O'Brien M et al. Seasonality of vitamin D status and bone turnover in patients with Crohn's disease. Aliment. Pharmacol. Ther. 21(9), 1073-1083 (2005).
82. Tajika M, Matsuura A, Nakamura T et al. Risk factors for vitamin D deficiency in patients with Crohn's disease. J. Gastroenterol. 39(6), 527-533 (2004).
83. Jahnsen J, Falch JA, Mowinckel P, Aadland E. Vitamin D status, parathyroid hormone and bone mineral density in patients with inflammatory bowel disease. Scand. J. Gastroenterol. 37(2), 192-199 (2002).
84. Sentongo TA, Semaeo EJ, Stettler N et al. Vitamin D status in children, adolescents, and young adults with Crohn disease. Am. J. Clin. Nutr. 76(5), 1077-1081 (2002).
85. Pappa HM, Gordon CM, Saslowsky TM et al. Vitamin D status in children and young adults with inflammatory bowel disease. Pediatrics 118(5), 1950-1961 (2006).
86. Bischoff-Ferrari HA, Dietrich T, Orav EJ et al. Positive association between 25-hydroxy vitamin D levels and bone mineral density: a population based study of younger and older adults. Am. J. Med. 116(9), 634-639 (2004).
87. Leslie WD, Miller N, Rogala L et al. Vitamin D status and bone density in recently diagnosed inflammatory bowel disease: the Manitoba IBD Cohort Study. Am. J. Gastroenterol. 103(6), 1451-1459 (2008).
88. Bernstein CN, Bector S, Leslie WD. Lack of relationship of calcium and vitamin D intake to bone mineral density in premenopausal women with inflammatory bowel disease. Am. J. Gastroenterol. 98(11), 2468-2473 (2003).
89. Pappa HM, Grand RJ, Gordon CM. Report on the vitamin D status of adult and pediatric patients with inflammatory bowel disease and its significance for bone health and disease. Inflamm. Bowel Dis. 12(12), 1162-1174 (2006).
90. Trang HM, Cole DE, Rubin LA, Pierratos A, Siu S. Vieth R. Evidence that vitamin D3 increases serum 25-hydroxyvitamin D more efficiently than does vitamin D2. Am. J. Clin. Nutr. 68(4), 854-858 (1998).
91. Armas LA, Hollis BW, Heaney RP. Vitamin D2 is much less effective than vitamin D3 in humans. J. Clin. Endocrinol. Metab. 89(11), 5387-5391 (2004).
92. Abitbol V, Mary JY, Roux C et al. Osteoporosis in inflammatory bowel disease: effect of calcium and vitamin D with or without fluoride. Aliment. Pharmacol. Ther. 16(5), 919-927 (2002).
93. Siffledeen JS, Fedorak RN, Siminoski K et al. Randomized trial of etidronate plus calcium and vitamin D for treatment of low bone mineral density in Crohn's disease. Clin. Gastroenterol. Hepatol. 3(2), 122-132 (2005).
94. Bartram SA, Peaston RT, Rawlings DJ et al. A randomized controlled trial of calcium with vitamin D, alone or in combination with intravenous pamidronate, for the treatment of low bone mineral density associated with Crohn's disease. Aliment. Pharmacol. Ther. 18(11-12), 1121-1127 (2003).
95. Benchimol EI, Ward LM, Gallagher JC et al. Effect of calcium and vitamin D supplementation on bone mineral density in children with inflammatory bowel disease. J. Pediatr. Gastroenterol. Nutr. 45(5), 538-545 (2007).
96. Rucker RB. Improved functional endpoints for use in vitamin K assessment: important implications for bone disease. Am. J. Clin. Nutr. 65(3), 883-884 (1997).
97. Schoon EJ, Müller MCA, Vermeer C, Schurgers LJ, Brummer RJ, Stockbrügger RW. Low serum and bone vitamin K status in patients with longstanding Crohn's disease: another pathogenetic factor of osteoporosis in Crohn's disease? Gut 48(4), 473-477 (2001).
98. Duggan P, O'Brien M, Kiely M et al. Vitamin K status in patients with Crohn's disease and relationship to bone turnover. Am. J. Gastroenterol. 99(11), 2178-2185 (2004).
99. Bousvaros A, Zurakowski D, Duggan C et al. Vitamins A and E serum levels in children and young adults with inflammatory bowel disease: effect of disease activity. J. Pediatr. Gastroenterol. Nutr. 26(2), 129-135 (1998).
100. Sturniolo GC, Fries W, Mazzon E, DiLeo V, Barollo M, D'inca R. Effect of zinc supplementation on intestinal permeability in experimental colitis. J. Lab. Clin. Med. 139(5), 311-315 (2002).
101. Griffin IJ, Kim SC, Hicks PD, Liang LK, Abrams SA. Zinc metabolism in adolescents with Crohn's disease. Pediatr. Res. 56(2), 235-239 (2004).
102. Dziechciarz P, Horvath A, Shamir R, Szajewska H. Meta-analysis: enteral nutrition in active Crohn's disease in children. Aliment. Pharmacol. Ther. 26, 795 (2007).
103. Heuschkel R, Menache CC, Megerian J et al. Enteral nutrition and corticosteroids in the treatment of acute Crohn's disease in children. J. Pediatr. Gastroenterol. Nutr. 31(1), 8-15 (2000).
104. Zachos M, Tondeur M, Griffiths AM. Enteral nutritional therapy for induction of remission in Crohn's disease. Cochrane Database Syst. Rev. 1, CD000542 (2007).
105. Gassull MA, Fernandez-Banares F, Cabre E et al. Fat composition may be a clue to explain the primary therapeutic effect of enteral nutrition in Crohn's disease: results of a double blind randomized multicentre European trial. Gut 51(2), 164-168 (2002).
106. Akobeng AK, Thomas AG. Enteral nutrition for maintenance of remission in Crohn's disease (Review). Cochrane Database Syst. Rev. 3, CD0005984 (2007).
107. Takagi S, Utsunomiya K, Kuriyama S et al. Effectiveness of a "half elemental diet" as maintenance therapy for Crohn's disease: a randomized controlled trial. Aliment. Pharmacol. Ther. 24(9), 1333-1340 (2006).
108. Verma S, Holdsworth CD, Giaffer MH. Does adjuvant nutritional support diminish steroid dependency in Crohn disease? Scand. J. Gastroenterol. 36(4), 383-388 (2001).
109. Johnson T, Macdonald S, Hill SM, Thomas A, Murphy MS. Treatment of active Crohn's disease in children using partial enteral nutrition with liquid formula: a randomized controlled trial. Gut 55, 356-361 (2006).
110. Sanderson IR, Udeen S, Davies PS et al. Remission induced by an elemental diet in small bowel Crohn's disease. Arch. Dis. Child. 62(2), 123-127 (1987).
111. Papadopoulou A, Rawashdeh MO, Brown GA et al. Remission following an elemental diet or prednisolone in Crohn's disease. Acta Paediatr. 84(1), 79-83 (1995).
112. Ruuska T, Savilahti E, Maki M, Ormälä T, Visakorpi JK. Exclusive whole protein enteral diet versus prednisolone in the treatment of acute Crohn's disease in children. J. Pediatr. Gastroenterol. Nutr. 19(2), 175-180 (1994).
113. Bannerjee K, Camacho-Hubner C, Babinska K et al. Anti-inflammatory and growth-stimulating effects precede nutritional restitution during enteral feeding in Crohn disease. J. Pediatr. Gastroenterol. Nutr. 38(3), 270-275 (2004).
114. Yamamoto T, Nakahigashi M, Saniabadi AR et al. Impacts of long-term enteral nutrition on clinical and endoscopic disease activities and mucosal cytokines during remission in patients with Crohn's disease: a prospective study. Inflamm. Bowel Dis. 13, 1493-1501 (2007).
115. Yamamoto T, Nakahigashi M, Umegae S, Kitagawa T, Matsumoto K. Impact of elemental diet on mucosal inflammation in patients with active Crohn's disease: cytokine production and endoscopic and histological findings. Inflamm. Bowel Dis. 11(6), 580-588 (2005).
116. Lionetti P, Callegari ML, Ferrari S et al. Enteral nutrition and microflora in pediatric Crohn's disease. JPEN J. Parent. Enteral Nutr. 29(4 Suppl.), S173-S178 (2005).
117. Nieto N, Torres MI, Ríos A et al. Dietary polyunsaturated fatty acids improve histological and biochemical alterations in rats with experimental ulcerative colitis. J. Nutr. 132(1), 11-19 (2002).
118. Whiting CV, Bland PW, Tarlton JF. Dietary n-3 polyunsaturated fatty acids reduce disease and colonic proinflammatory cytokines in a mouse model of colitis. Inflamm. Bowel Dis. 11(4), 340-349 (2005).
119. Camuesco D, Comalada M, Concha A et al. Intestinal anti-inflammatory activity of combined quercitrin and dietary olive oil supplemented with fish oil, rich in EPA and DHA (n-3) polyunsaturated fatty acids, in rats with DSS-induced colitis. Clin. Nutr. 25(3), 466-476 (2006).
120. Bassaganya-Riera J, Hontecillas R. CLA and n-3 PUFA differentially modulate clinical activity and colonijc PPAR-responsive gene expression in a pig model of experimental IBD. Clin. Nutr. 25(3), 454-465 (2006).
121. Bjorkkjaer T, Brunborg LA, Arslan G et al. Reduced joint pain after short-term duodenal administration of seal oil in patients with inflammatory bowel disease: comparison with soy oil. Scand. J. Gastroenterol. 39(11), 1088-1094 (2004).
122. Nielsen AA, Jørgensen LG, Nielsen JN et al. Omega-3 fatty acids inhibit an increase of porinflammatory cytokines in patients with active Crohn's disease compared with omega-6 fatty acids. Aliment. Pharmacol. Ther. 22, 1121-1128 (2005).
123. Romano C, Cucchiara S, Barabino A, Annese V, Sferlazzas C. Usefulness of omega-3 fatty acid supplementation in addition to mesalazine in maintaining remission in pediatric Crohn's disease: a double-blind, randomized, placebo-controlled study. World J. Gastroenterol. 11(45), 7118-7121 (2005).
124. Belluzzi A, Brignola C, Campieri M, Pera A, Boschi S, Miglioli M. Effect of an enteric-coated fish-oil preparation on relapses in Crohn's disease. N. Engl. J. Med. 334(24), 1557-1560 (1996).
125. Feagan BG, Sandborn WJ, Mittman U et al. Omega-3 free fatty acids for the maintenance of remission in Crohn disease: the EPIC randomized controlled trials. JAMA 299(14), 1690-1697 (2008).
126. Turner D, Zlotkin SH, Shah PS, Griffiths AM. Omega 3 fatty acids (fish oil) for maintenance of remission in Crohn's disease (Review). Cochrane Database Syst. Rev. 1, CD006320 (2009).
127. Turner D, Steinhart AH, Griffiths AM. Omega 3 fatty acids (fish oil) for maintenance of remission in ulcerative colitis. Cochrane Database Syst. Rev. 3, CD006443 (2007).
128. Varilek GW, Yang F, Lee EY et al. Green tea polyphenol extract attenuates inflammation in interleukin-2-deficient mice, a model of autoimmunity. J. Nutr. 131, 2034-2039 (2001).
129. Mazzon E, Muia C, Paola RD et al. Green tea polyphenol extract attenuates colon injury induced by experimental colitis. Free Radic. Res. 39, 1017-1025 (2005).
130. Nomura M, Ma W, Chen N, Bode AM, Dong Z. Inhibition of 12-O-tetradecanoylphorbol-13-acetate-induced NF-κb activation by tea polyphenols, (-)-epigallocatechin gallate and theaflavins. Carcinogenesis 21(10), 1885-1890 (2000).
131. Lubbad A, Oriowo MA, Khan I. Curcumin attenuates inflammation through inhibition of TLR-4 receptor in experimental colitis. Mol. Cell. Biochem. 322 (1-2), 127-135 (2009).
132. Nones K, Dommels YE, Martell S et al. The effects of dietary curcumin and rutin on colonic inflammation and gene expression in multidrug resistance gene-deficient (mdr1a-/-) mice, a model of inflammatory bowel diseases. Br. J. Nutr. 101 (2), 169-181 (2009).
133. Holt PR, Katz S, Kirshoff R. Curcumin therapy in inflammatory bowel disease: a pilot study. Dig. Dis. Sci. 50(11), 2191-2193 (2005).
134. Mishkin B, Yalovsky M, Mishkin S. Increased prevalence of lactose malabsorption in Crohn's disease patients at low risk for lactose malabsorption based on ethnic origin. Am. J. Gastroenterol. 92(7), 1148-1153 (1997).
135. Bernstein CN, Katz S. Guidelines For Osteoporosis And Inflammatory Bowel Disease. A Guide To Diagnosis And Management For The Gastroenterologist (Monograph). The American College of Gastroenterology, MD, USA (2003).